Add this topic to your myFT Digest for news straight to your inbox
Dean at centre of Christ Church dispute agrees to step down, accepting offer of almost £1.2mn
VB variant is highly virulent and transmissible but responsive to antiretroviral therapy, study shows
Christ Church under pressure to end long-running clash with dean by agreeing £1.5m pay-off and settling sexual harassment claim
The apparent efficacy of its booster against Omicron could shore up the jab’s shaky position among competitors
Pharma group says it is confident its Covid vaccine ‘should be given as a third dose booster’
Global health authorities have voiced concern that current jabs may afford less protection against variant
Poonawalla family donation will build labs for university Jenner Institute
VietJet founder Nguyen Thi Phuong Thao’s $211m gift to Linacre draws criticism
Louise Richardson says ‘informality’ and ‘flexibility’ are key in leading an ancient university with its disputatious devolved colleges
Key members of Oxford’s scientific team reveal the exhaustive effort and care that went into the race to create a ‘vaccine for the world’
Peter Lampl put his financial muscle into boosting educational access for all — but the pandemic has made progress harder than ever
Sculptor says move would help to address ‘collective amnesia’ over memorials
Sasha Johnson supporters hit out after London force says ‘nothing to suggest’ attack was targeted
Student group finds 1,000 workers were paid below city’s living wage of £10.31 an hour
We at the university, alongside the drugmaker, felt we should not profiteer from a pandemic
Property investors pile into life sciences sector as part of shift away from retail and offices
Declining infection rates mean potential risks from jab may outweigh dangers of disease
Jab developed by University of Oxford team proves 77% effective in Burkina Faso mid-stage tests
Some on vaccine committee take cautious line over blood clots, while others fear impact on inoculation rollout
Brussels puts focus on mRNA vaccines amid concern over rare blood clots linked to other shots
Decision to restrict jab only for people under 30 contrasts with tougher stance in other countries
Clinical testing of jab with small group aged 6-17 suspended ahead of risk review from regulators
Hamilton Lane denies targeting professor who published study that rocked industry
Intranasal vaccines would be easier to administer and could cut transmission rates
History provides a window into how the coronavirus outbreak might come to a close
International Edition